上海复宏瑞霖

Henlius Ruilin is a specialized biopharmaceutical subsidiary of Henlius (Shanghai Henlius Biotech) dedicated to the development of innovative ophthalmic therapies. The company focuses on addressing high-prevalence retinal diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Its lead candidate, HLX04-O, is a recombinant humanized anti-VEGF monoclonal antibody that has entered global Phase 3 clinical trials. By leveraging the integrated biologics platform of its parent company, Henlius Ruilin aims to provide high-quality and accessible treatment options for patients worldwide. The company represents a strategic expansion of the Henlius portfolio into the vision care sector.